Compile Data Set for Download or QSAR
Report error Found 328 Enz. Inhib. hit(s) with all data for entry = 9280
TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455104(US10730874, Compound I-125)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455105(US10730874, Compound I-126 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455100(US10730874, Compound I-121 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455101(US10730874, Compound I-122)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455098(US10730874, Compound I-119)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455099(US10730874, Compound I-120 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455096(US10730874, Compound I-117 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455094(US10730874, Compound I-115 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455093(US10730874, Compound I-114 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455090(US10730874, Compound I-111 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455091(US10730874, Compound I-112 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455120(US10730874, Compound I-141 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455118(US10730874, Compound I-139 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455119(US10730874, Compound I-140 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455116(US10730874, Compound I-137 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455117(US10730874, Compound I-138 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455114(US10730874, Compound I-135 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455115(US10730874, Compound I-136 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455112(US10730874, Compound I-133)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455113(US10730874, Compound I-134 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455110(US10730874, Compound I-131 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455111(US10730874, Compound I-132 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455108(US10730874, Compound I-129 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455106(US10730874, Compound I-127)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455107(US10730874, Compound I-128 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455136(US10730874, Compound I-157a | US11352356, Compound...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455137(US10730874, Compound I-157b | US11352356, Compound...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455134(US10730874, Compound I-155)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455135(US10730874, Compound I-156 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455132(US10730874, Compound I-153 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455133(US10730874, Compound I-154 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455131(US10730874, Compound I-152 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455128(US10730874, Compound I-149 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455129(US10730874, Compound I-150 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455127(US10730874, Compound I-148)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455124(US10730874, Compound I-145 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455125(US10730874, Compound I-146 | US10730874, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455122(US10730874, Compound I-143 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455123(US10730874, Compound I-144)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455152(US10730874, Compound I-170)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455153(US10730874, Compound I-171 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455150(US10730874, Compound I-168 | US10730874, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455151(US10730874, Compound I-169 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455147(US10730874, Compound I-166a | US10730874, Compound...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455149(US10730874, Compound I-167 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455146(US10730874, Compound I-165 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455147(US10730874, Compound I-166a | US10730874, Compound...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455144(US10730874, Compound I-163b | US11352356, Compound...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455145(US10730874, Compound I-164 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

Displayed 1 to 50 (of 328 total ) | Next | Last >>
Jump to: